How much does retatrutide cost? Is there an approved price?

Is there an approved retatrutide price in Australia?

The records checked on 17 October 2026 give no price for an approved Australian retatrutide medicine. The TGA reviews medicines in Australia. Its alert of 14 September 2026 says retatrutide has no TGA approval. It also reports no approval from a similar body overseas. This tells you about approval, without announcing a price. A shop listing cannot give a medicine that missing approval. Calling an online figure a pharmacy price would mix up those roles. Start with the named product's approval record. If an approved product reaches the market, look for a separate price record.

For the wider status question, read Retatrutide in Australia: is it legal, approved or available yet?. That page checks the Australian record. It does not guess a launch cost.

How much will retatrutide cost per month?

Lilly's September 2026 FAQ gives no future monthly cost for retatrutide (checked 17 October 2026). Lilly discusses pricing after trials in people and review by medicine authorities. It gives no amount. A plan for setting a price is not a published list price. A list price is the maker's stated price for a named product in a named market. The FAQ cannot show that future price or an Australian pharmacy charge. Nor can it show how much the PBS would pay. Guessing a cost would make an unknown seem like a fact.

Approval in another country would need its own dated record. What does the public record say about retatrutide in the United States? covers that question. A US status update alone would not show an Australian price.

Who decides whether a medicine has a PBS price?

Approval alone does not set a PBS price. A medicine must go through a separate Australian listing process. The Pharmaceutical Benefits Scheme, or PBS, helps pay for listed medicines. Its advice group, the PBAC, checks the evidence and costs for a proposed listing. PBS guidance explains what follows when this group backs a listing (checked 17 October 2026). The maker and health department discuss the price. Further work covers listing details and checks on quality and supply. The government must also consider it. A maker's public list price and a PBS deal mean different things. Neither comes straight from a trial paper.

The same PBS guidance explains where listed medicines appear (checked 17 October 2026). They appear in the Schedule of Pharmaceutical Benefits, the list of covered medicines. A committee's backing is one step toward that record. The word Recommended is not a price tag.

What do the tirzepatide and semaglutide PBAC records show?

These PBAC records back listings for set groups of people. They do not predict a retatrutide price. The March 2026 outcome backs tirzepatide for adults whose type 2 diabetes is not well controlled. The November 2025 outcome backs semaglutide for a set adult group. That group has known heart or blood vessel disease and obesity. Both entries were checked on 17 October 2026. Each decision covers its named medicine and group. Neither entry gives a date when a PBS listing starts. You need to read each committee outcome with care. Backing one listing cannot show the price or listing of another compound.

Read What did the March 2026 PBAC decide on tirzepatide? for a summary tied to that meeting date. The source documents above give both examples in full.

Evidence limits

Can research listings or trial papers establish a medicine price?

How are people getting retatrutide? separates trial records from claims made outside trials. The Form Laboratories research catalogue lists research material. Research material is not an approved medicine or a replacement for one. It is not for human or animal use.